Real-World check: does bosutinib control CML safely?

NCT ID NCT02501330

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the disease. The goal is to gather real-world information on the drug's risks and benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bosutinib (brand name Bosulif)
What this could lead to: If successful, this study could confirm that bosutinib is a safe and effective option for controlling CML in a broad range of patients.
What could go wrong: This is an observational surveillance study, not a controlled trial, so results may not prove cause and effect. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.